Alan Breier, MD

Psychiatry Department, Indiana University School of Medicine, Indianapolis, Indiana

JCP
Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia
Original Research

March 24, 2025

Xanomeline and trospium showed improvement in agitation as measured by the PANSS-Excited Component in participants with acute exacerbations of schizophrenia.
, , , et al
JCP
Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia
Narrative Review

August 19, 2024

While the pathophysiology of schizophrenia is complex, treatments with novel pharmacological actions that target these systems are of interest as adjunctive treatment for schizophrenia.
, , , et al
JCP
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)
Original Research

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ May 11, 2022

This post hoc analysis of phase 2 data evaluated rates and time course of response with the new combination oral agent KarXT (xanomeline−trospium) in the treatment of schizophrenia.
, , , et al
JCP
Original Research

December 15, 2009

, , , et al
JCP
Original Research

March 24, 2009

, , , et al
JCP
Original Research

July 15, 2005

, , , et al
JCP
Original Research

September 15, 2003

, , , et al
JCP
Article

February 1, 2001

JCP
Original Research

January 1, 2001

, , , et al
JCP
Original Research

October 31, 2000

, , , et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe